Phase 3 Readout~month

Phase 3 Topline: Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor

Indication
Breast Cancer

Other upcoming events for RANI

Patent ExpiryPatent/Exclusivity Expiry: ORSERDU

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor — RANI Phase 3 Readout | BioSniper